Hydrochlorothiazide 25 mg

DRUG6 trials

Sponsors

Creighton University, Profil Institut für Stoffwechselforschung GmbH, University Hospital Tuebingen, Jiangsu HengRui Medicine Co., Ltd., University Medical Center Groningen

Conditions

ADPKDHypertensionType 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

Phase 1

Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension

CompletedNCT03971929

Jiangsu HengRui Medicine Co., Ltd.Hypertension

Start: 2019-07-31End: 2020-09-03Updated: 2021-10-18

Phase 3

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

RecruitingNCT05373264

University Medical Center GroningenADPKD

Start: 2024-07-31End: 2031-07-01Target: 300Updated: 2026-08-25

Phase 4

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

WithdrawnNCT01822860

Creighton UniversityHypertension

Start: 2013-03-31End: 2015-02-28Updated: 2015-03-25

Chlorthalidone and HCTZ Impacts on Platelet Activation

Creighton UniversityHypertension

Start: 2014-03-31End: 2016-12-31Target: 30Updated: 2015-12-14

Empagliflozin and Sympathetic Nerve Traffic

CompletedNCT03254849

Profil Institut für Stoffwechselforschung GmbHType 2 Diabetes Mellitus

Start: 2017-12-08End: 2020-04-20Updated: 2020-07-14

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

WithdrawnNCT03423355

University Hospital TuebingenType 2 Diabetes Mellitus (T2DM)

Start: 2021-09-30End: 2023-12-31Updated: 2021-12-15